Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic monoclonal antibody.
Read the full article on WikipediaMultiple sclerosis Clinical criteria: Treatment Phase: Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition, AND Patient must not show continuing progression of disability while on treatment with this drug, AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition, AND Patient must have demonstrated compliance with, and an ability to tolerate this therapy. Treatment criteria: Must be treated by a neurologist.
Working under the parallel aged-care framework? Aged-care equivalent →